MX2021005863A - Anticuerpos antiestafilococo y usos de estos. - Google Patents

Anticuerpos antiestafilococo y usos de estos.

Info

Publication number
MX2021005863A
MX2021005863A MX2021005863A MX2021005863A MX2021005863A MX 2021005863 A MX2021005863 A MX 2021005863A MX 2021005863 A MX2021005863 A MX 2021005863A MX 2021005863 A MX2021005863 A MX 2021005863A MX 2021005863 A MX2021005863 A MX 2021005863A
Authority
MX
Mexico
Prior art keywords
antibodies
antigen
compositions
binding fragments
staphylococcal
Prior art date
Application number
MX2021005863A
Other languages
English (en)
Spanish (es)
Inventor
Christos Kyratsous
Alida Coppi
Brinda Prasad
Anna Zumsteg
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2021005863A publication Critical patent/MX2021005863A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2021005863A 2018-11-21 2019-11-20 Anticuerpos antiestafilococo y usos de estos. MX2021005863A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862770608P 2018-11-21 2018-11-21
US201962822029P 2019-03-21 2019-03-21
US201962865436P 2019-06-24 2019-06-24
PCT/US2019/062370 WO2020106814A1 (en) 2018-11-21 2019-11-20 Anti-staphylococcus antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2021005863A true MX2021005863A (es) 2021-07-16

Family

ID=68848487

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021005863A MX2021005863A (es) 2018-11-21 2019-11-20 Anticuerpos antiestafilococo y usos de estos.

Country Status (16)

Country Link
US (2) US12024556B2 (cg-RX-API-DMAC7.html)
EP (1) EP3883963A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022512904A (cg-RX-API-DMAC7.html)
KR (1) KR20210093856A (cg-RX-API-DMAC7.html)
CN (1) CN112867732A (cg-RX-API-DMAC7.html)
AU (1) AU2019384790A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021005522A2 (cg-RX-API-DMAC7.html)
CA (1) CA3110377A1 (cg-RX-API-DMAC7.html)
CL (2) CL2021001307A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021003752A2 (cg-RX-API-DMAC7.html)
IL (1) IL281056A (cg-RX-API-DMAC7.html)
MA (1) MA55134A (cg-RX-API-DMAC7.html)
MX (1) MX2021005863A (cg-RX-API-DMAC7.html)
PH (1) PH12021550538A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202102060PA (cg-RX-API-DMAC7.html)
WO (1) WO2020106814A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023208123A1 (zh) * 2022-04-28 2023-11-02 珠海泰诺麦博制药股份有限公司 特异性结合金黄色葡萄球菌Hla毒素的全人源单克隆抗体
GB202311984D0 (en) * 2023-08-04 2023-09-20 Petmedix Ltd Optimised fc molecules
CN118580347B (zh) * 2024-05-13 2025-02-07 重庆原伦生物科技有限公司 一种抗金黄色葡萄球菌蛋白a的单克隆抗体及其应用
CN120943954B (zh) * 2025-10-20 2026-02-06 重庆原伦生物科技有限公司 抗金黄色葡萄球菌IsdB抗体的制备及其应用
CN120988116B (zh) * 2025-10-24 2025-12-30 重庆原伦生物科技有限公司 针对金黄色葡萄球菌IsdB的抗体及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20030224000A1 (en) * 2001-12-21 2003-12-04 Kokai-Kun John Fitzgerald Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
CA2606102C (en) 2005-04-26 2014-09-30 Medimmune, Inc. Modulation of antibody effector function by hinge domain engineering
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
US7488807B2 (en) * 2006-11-22 2009-02-10 3M Innovative Properties Company Antibody with protein A selectivity
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
WO2012122533A2 (en) * 2011-03-10 2012-09-13 The University Of Chicago Compositions and methods related to antibodies to staphylococcal proteins isda or isdb
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
WO2013096948A1 (en) * 2011-12-23 2013-06-27 Lydon Nicholas B Immunoglobulins and variants directed against pathogenic microbes
FI3366705T3 (fi) 2012-09-12 2023-07-28 Genzyme Corp Muuttuneen glykosylaation ja vähentyneen efektoritoiminnan omaavia fc:n sisältäviä polypeptidejä
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
AR101262A1 (es) 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
JP2018517708A (ja) 2015-06-05 2018-07-05 ニューヨーク・ユニバーシティ 抗ブドウ球菌生物学的薬剤のための組成物及び方法
GB201602156D0 (en) 2016-02-05 2016-03-23 Jones Philip C And Boku University Of Natural Resources And Life Sciences Heterodimers and purification thereof
TW202311284A (zh) * 2017-01-03 2023-03-16 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素a毒素之人類抗體
AU2018281280B2 (en) 2017-06-07 2024-12-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
BR112020004977A2 (pt) * 2017-09-29 2020-10-06 Regeneron Pharmaceuticals, Inc. moléculas de ligação de antígenos biespecíficas que ligam antígeno alvo de staphyocococcus e componente de complemento e usos dos mesmos

Also Published As

Publication number Publication date
KR20210093856A (ko) 2021-07-28
SG11202102060PA (en) 2021-03-30
EP3883963A1 (en) 2021-09-29
CA3110377A1 (en) 2020-05-28
IL281056A (en) 2021-04-29
CO2021003752A2 (es) 2021-04-19
JP2022512904A (ja) 2022-02-07
US12024556B2 (en) 2024-07-02
AU2019384790A1 (en) 2021-03-18
CL2023003084A1 (es) 2024-04-12
WO2020106814A1 (en) 2020-05-28
US20240301041A1 (en) 2024-09-12
US20200157193A1 (en) 2020-05-21
MA55134A (fr) 2021-09-29
CN112867732A (zh) 2021-05-28
BR112021005522A2 (pt) 2021-06-29
CL2021001307A1 (es) 2021-11-05
PH12021550538A1 (en) 2022-02-21

Similar Documents

Publication Publication Date Title
PH12021550538A1 (en) Anti-staphylococcus antibodies and uses thereof
ZA202206437B (en) Claudin18.2 binding moieties and uses thereof
MX2020009121A (es) Uso de anticuerpos sirpa v1 antihumanos y procedimiento de produccion de anticuerpos anti-sirpa v1.
ZA202100723B (en) Fc binding fragments comprising a cd137 antigen-binding site
SG196697A1 (en) Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
AU2017297757A1 (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
HK1252666A1 (zh) 针对cd40的抗体
WO2005110474A3 (en) HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
WO2019165122A8 (en) Neutralizing antibodies to hiv-1 env and their use
PH12020550025A1 (en) Multispecific antibodies specifically binding to zika virus epitopes and uses thereof
WO2020172621A8 (en) Cd33 antibodies and methods of using the same to treat cancer
EP4406550A3 (en) Antibodies to cd40 with enhanced agonist activity
EP4530296A3 (en) Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
WO2020076789A3 (en) Combinations of anti-staphylococcus aureus antibodies
PH12021552903A1 (en) Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof
WO2016145385A3 (en) Pan-ebola and pan-filovirus protective epitopes, antibodies, and antibody cocktails
EA201990895A1 (ru) Антитела к о1 и варианты их применения
EA201990222A1 (ru) Антитела к o2 и пути их применения
WO2021050857A8 (en) Anti-cd371 antibodies and uses thereof
WO2013089877A3 (en) Adjuvant therapy for staphylococcal infection with enterotoxin specific mabs
WO2020191181A9 (en) Monoclonal antibodies for prevention and treatment of herpes simplex viral infections
MX2009008754A (es) Anticuerpos novedosos contra igf-1r.
WO2023129870A3 (en) ANTIBODIES SPECIFICALLY RECOGNIZING C5aR1 AND USES THEREOF
WO2021041300A3 (en) Bispecific antibodies and uses thereof
WO2021058711A3 (en) Antigen binding proteins